TSX · IGX.TO
IntelGenx Technologies Corp.
CA$0.24+CA$0.04 (+17.07%)
IntelGenx Technologies Corp.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
Loading market information…
TSX · CSCI.TO · CAD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 07:20 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
COSCIENS Biopharma Inc.’s forward annual dividend is CA$44,549.91 per share, paid quarterly. The forward yield is 494,999.02% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
COSCIENS Biopharma Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -CA$2.54. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow COSCIENS Biopharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| CA$132.54K-91.1% vs estimate |
| Q3 2024 | Nov 7, 2024 | -CA$7.51+46.84% vs estimate | CA$2.57M+72.73% vs estimate |
|---|
| Q2 2024 | Aug 13, 2024 | -CA$2.63+80.49% vs estimate | CA$3.15M+109.09% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.24+CA$0.04 (+17.07%)
IntelGenx Technologies Corp.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
CA$0.53+CA$0.02 (+3.92%)
HS GovTech Solutions Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
CA$0.97-CA$0.18 (-15.65%)
Greenbrook TMS Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.32% below the high.
CA$0.02+CA$0.01 (+33.33%)
MedMen Enterprises Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
CA$0.58+CA$0.01 (+1.75%)
Acasti Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.59% below the high.
CA$0.32+CA$0.01 (+1.61%)
Think Research Corporation’s quoted price sits in the upper half of its reported 52-week range, 26.74% below the high.
CA$0.20-CA$0.01 (-4.76%)
Vinergy Capital Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
CA$1.42-CA$0.04 (-2.74%)
Reunion Neuroscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.96% below the high.
